Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

To join this study, people must have clear cell renal cell carcinoma that has either returned or not responded to previous treatments. Doctors need to be able to measure your cancer using scans. You also need to be generally well and able to carry out your normal daily activities without too much difficulty, as assessed by a doctor. It's also important that doctors can get a sample of your tumour tissue for testing.

There are also some reasons why people might not be able to join. For example, if you've already had a similar experimental treatment, or if you've had a bad allergic reaction to other antibody medicines in the past. If you've recently had other cancer treatments, you might need to wait a certain amount of time before joining. People with brain cancer that is causing symptoms or getting worse, or with serious active infections, would also not be able to take part.

Some long-term health conditions, like certain autoimmune diseases, might also prevent you from joining, especially if they are severe or need strong treatments. However, some milder conditions, like vitiligo or well-controlled thyroid problems, might still allow you to participate.

If you decide to take part in this study, you will receive the new medicine, XmAb®819, either through a drip into your vein or as an injection under your skin. The exact schedule for how often you receive the medicine will be set by the study doctors. You will have regular visits to the clinic so the research team can carefully monitor your health, check for any side effects, and see how the medicine is working. These visits will likely involve physical exams, blood tests, and scans to measure your cancer. The length of time you'll be on the study treatment will vary depending on how you respond to the medicine and if you experience any side effects. You will have follow-up appointments after stopping treatment to continue monitoring your health.